Description

Drug Classification:

Ranitidine belongs to the class of drugs known as H2-receptor antagonists. It works by selectively blocking the histamine H2 receptors in the stomach, thereby reducing the production of gastric acid and alleviating symptoms associated with hyperacidity.

Formulations:

• Ranitidine Tablets:
  • Strength: Each tablet contains 150 mg of Ranitidine.
  • Product Form: Oral tablets for convenient administration.
  • Packing Specifications: Packaged in blister packs containing 10 tablets each.
• Ranitidine Injection:
  • Strength: Each ampule contains 50mg of Ranitidine.
  • Product Form: Liquid solution for intravenous administration.
  • Packing Specifications: Packaged in ampules containing 5 injections each.

Indications:

Ranitidine Tablets and Injection are indicated for the treatment of various gastric acid-related disorders, including:

• Peptic ulcers (duodenal and gastric ulcers)
• Benign gastric ulceration
• Zollinger-Ellison syndrome
• Gastroesophageal reflux disease (GERD)
• Erosive esophagitis
• Pathological hypersecretory conditions

Usage:

• Ranitidine Tablets should be taken orally with or without food, as directed by a healthcare professional.
• Ranitidine Injection is administered via intravenous infusion under medical supervision.

Dosage:

• The dosage of Ranitidine may vary depending on the severity of the condition being treated and the patient’s individual response.
• For the treatment of peptic ulcers and GERD, the usual adult dosage is 150 mg twice daily or 300 mg at bedtime.
• In cases of Zollinger-Ellison syndrome and other hypersecretory conditions, higher doses may be required, as determined by a healthcare provider.

Pharmacokinetics:

• Ranitidine is well-absorbed from the gastrointestinal tract after oral administration, with peak plasma concentrations achieved within 2-3 hours.
• The drug undergoes extensive hepatic metabolism, primarily via oxidation and conjugation, followed by renal excretion of metabolites.
• Ranitidine has a plasma half-life of approximately 2-3 hours in healthy individuals, but this may be prolonged in patients with renal impairment.

Pharmacodynamics:

• Ranitidine exerts its pharmacological effects by competitively inhibiting the action of histamine at the H2 receptors on gastric parietal cells.
• By reducing gastric acid secretion, Ranitidine effectively promotes ulcer healing, relieves symptoms of acid reflux, and prevents recurrence of peptic ulcers.

Side Effects:

• Common side effects of Ranitidine may include headache, dizziness, constipation, and diarrhea.
• Rare but serious side effects may include allergic reactions, liver dysfunction, and blood disorders.
• Patients should be monitored for any adverse reactions during treatment with Ranitidine, and healthcare providers should be informed of any concerning symptoms.

Experience the relief provided by AIT Pharmaceuticals Division’s Ranitidine Tablets and Injection for gastric acid-related disorders. For more information, please contact us. We are committed to delivering effective pharmaceutical solutions to healthcare professionals worldwide.